Displaying 33 (all) recruiting clinical trials.
-
A Phase 1/2 Study Evaluating the Safety and Efficacy of Amivantamab and Olomorasib Combination Therapy in Metastatic NSCLC KaRAnaSa (ISA-4)
This is a study in which patients have a specific change in their cancer cells called a KRAS G12C mutation, which means one tiny part ...
Phase
Interventional
-
Phase 1/2 Study of mRNA-4359 Administered Alone and in Combination with Immune Checkpoint Blockade in Participants with Advanced Solid Tumors
This is a Phase 1/2 study testing a new drug called mRNA-4359 in people who have solid tumors: a type of cancer that can ...
Phase
Interventional
-
A Phase 1/2a Open-label Study of VS-7375 a KRAS G12D (ON/OFF) Inhibitor as Monotherapy and in Combination in Patients with Advanced KRAS G12D-Mutant Solid Tumors
VS-7375 is a highly selective oral, non-covalent, small molecule KRAS G12D inhibitor. VS-7375 demonstrated potent inhibition of KRAS G12D-mutated-dependent signal transduction and cancer cell viability ...Phase
Interventional
